Jacqueline Suen Garcia, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 32 | 2024 | 3523 | 4.470 |
Why?
|
Myelodysplastic Syndromes | 11 | 2024 | 1352 | 2.330 |
Why?
|
Azacitidine | 11 | 2024 | 347 | 1.700 |
Why?
|
Sulfonamides | 12 | 2024 | 1938 | 1.660 |
Why?
|
fms-Like Tyrosine Kinase 3 | 4 | 2023 | 491 | 1.010 |
Why?
|
Graft vs Host Disease | 2 | 2024 | 2957 | 0.790 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2024 | 5442 | 0.770 |
Why?
|
Mycoses | 1 | 2022 | 376 | 0.660 |
Why?
|
Antineoplastic Agents | 8 | 2023 | 13695 | 0.660 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 11524 | 0.600 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2021 | 640 | 0.590 |
Why?
|
Staurosporine | 1 | 2017 | 251 | 0.570 |
Why?
|
Boron Compounds | 1 | 2015 | 178 | 0.490 |
Why?
|
Protein Kinase Inhibitors | 3 | 2023 | 5535 | 0.450 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2016 | 651 | 0.440 |
Why?
|
Mitochondria | 3 | 2020 | 3520 | 0.430 |
Why?
|
Glycine | 1 | 2015 | 671 | 0.420 |
Why?
|
Cytarabine | 3 | 2020 | 692 | 0.360 |
Why?
|
Apoptosis | 4 | 2020 | 9727 | 0.340 |
Why?
|
Drug Discovery | 1 | 2017 | 1058 | 0.330 |
Why?
|
Patient Selection | 1 | 2020 | 4215 | 0.320 |
Why?
|
Leukemia | 3 | 2022 | 1511 | 0.290 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2024 | 1434 | 0.280 |
Why?
|
Mutation | 8 | 2024 | 29786 | 0.280 |
Why?
|
Transplantation, Homologous | 3 | 2024 | 4776 | 0.270 |
Why?
|
Myeloproliferative Disorders | 2 | 2021 | 606 | 0.260 |
Why?
|
Remission Induction | 4 | 2023 | 2386 | 0.250 |
Why?
|
Nuclear Proteins | 2 | 2016 | 5853 | 0.240 |
Why?
|
Graft vs Leukemia Effect | 1 | 2024 | 111 | 0.230 |
Why?
|
Recurrence | 4 | 2024 | 8340 | 0.210 |
Why?
|
Humans | 45 | 2024 | 744343 | 0.210 |
Why?
|
Neutropenia | 2 | 2024 | 895 | 0.200 |
Why?
|
Dancing | 1 | 2022 | 101 | 0.190 |
Why?
|
Busulfan | 1 | 2021 | 263 | 0.190 |
Why?
|
Thrombocythemia, Essential | 1 | 2021 | 105 | 0.190 |
Why?
|
Vidarabine | 1 | 2021 | 345 | 0.180 |
Why?
|
Polycythemia Vera | 1 | 2021 | 164 | 0.180 |
Why?
|
Hematology | 1 | 2023 | 221 | 0.180 |
Why?
|
Transplantation Conditioning | 2 | 2024 | 1598 | 0.180 |
Why?
|
Mitoxantrone | 1 | 2019 | 152 | 0.180 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 407 | 0.170 |
Why?
|
Clinical Trials as Topic | 3 | 2021 | 7913 | 0.160 |
Why?
|
Etoposide | 1 | 2019 | 641 | 0.160 |
Why?
|
Pyrimidines | 2 | 2020 | 2942 | 0.160 |
Why?
|
Azepines | 1 | 2019 | 336 | 0.150 |
Why?
|
Immunotherapy | 2 | 2023 | 4445 | 0.150 |
Why?
|
Antifungal Agents | 1 | 2022 | 730 | 0.150 |
Why?
|
Thiophenes | 1 | 2020 | 588 | 0.140 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.130 |
Why?
|
Recombinant Fusion Proteins | 1 | 2024 | 3772 | 0.130 |
Why?
|
Bone Marrow | 2 | 2023 | 2948 | 0.130 |
Why?
|
Immunophenotyping | 2 | 2019 | 1880 | 0.130 |
Why?
|
Immunotherapy, Adoptive | 1 | 2023 | 1270 | 0.120 |
Why?
|
Superoxides | 1 | 2015 | 387 | 0.120 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2019 | 1375 | 0.120 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2020 | 5172 | 0.120 |
Why?
|
Molecular Targeted Therapy | 2 | 2023 | 2727 | 0.120 |
Why?
|
Disease-Free Survival | 2 | 2022 | 6895 | 0.120 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 1519 | 0.120 |
Why?
|
Protein Transport | 2 | 2016 | 1988 | 0.110 |
Why?
|
Glutathione | 1 | 2015 | 589 | 0.110 |
Why?
|
Drug Interactions | 1 | 2017 | 1460 | 0.110 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1782 | 0.110 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2073 | 0.100 |
Why?
|
Ribosomes | 1 | 2015 | 500 | 0.100 |
Why?
|
Signal Transduction | 5 | 2023 | 23403 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3597 | 0.100 |
Why?
|
Adult | 10 | 2024 | 214055 | 0.100 |
Why?
|
Cytoplasm | 1 | 2015 | 1539 | 0.100 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 789 | 0.090 |
Why?
|
Oxidation-Reduction | 1 | 2015 | 2187 | 0.090 |
Why?
|
Hospitals | 1 | 2023 | 3952 | 0.090 |
Why?
|
Disease Management | 1 | 2019 | 2459 | 0.080 |
Why?
|
Autophagy | 1 | 2016 | 1300 | 0.080 |
Why?
|
Janus Kinase 2 | 2 | 2021 | 528 | 0.080 |
Why?
|
Reactive Oxygen Species | 1 | 2015 | 2077 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3557 | 0.080 |
Why?
|
RNA-Binding Proteins | 1 | 2016 | 1903 | 0.080 |
Why?
|
Treatment Outcome | 5 | 2023 | 63114 | 0.070 |
Why?
|
Aged | 9 | 2024 | 163280 | 0.070 |
Why?
|
Lymphoma | 1 | 2016 | 1877 | 0.070 |
Why?
|
Survival Rate | 1 | 2021 | 12788 | 0.070 |
Why?
|
Age Factors | 2 | 2020 | 18370 | 0.070 |
Why?
|
Cell Survival | 1 | 2015 | 5882 | 0.070 |
Why?
|
Flow Cytometry | 1 | 2015 | 5974 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9239 | 0.060 |
Why?
|
Prognosis | 3 | 2023 | 29063 | 0.060 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 1 | 2024 | 39 | 0.060 |
Why?
|
Middle Aged | 8 | 2022 | 213383 | 0.060 |
Why?
|
Aged, 80 and over | 4 | 2020 | 57776 | 0.050 |
Why?
|
Cell Line, Tumor | 2 | 2016 | 16689 | 0.050 |
Why?
|
Philadelphia Chromosome | 1 | 2022 | 112 | 0.050 |
Why?
|
Female | 10 | 2023 | 380194 | 0.050 |
Why?
|
Gene Expression | 1 | 2015 | 7799 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 12804 | 0.050 |
Why?
|
Proteins | 1 | 2016 | 6103 | 0.050 |
Why?
|
Anthracyclines | 1 | 2023 | 288 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2015 | 7722 | 0.050 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 345 | 0.050 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18029 | 0.050 |
Why?
|
Idarubicin | 1 | 2019 | 62 | 0.050 |
Why?
|
Leukopenia | 1 | 2020 | 212 | 0.040 |
Why?
|
Male | 8 | 2022 | 350118 | 0.040 |
Why?
|
Molecular Biology | 1 | 2023 | 596 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2023 | 77449 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 692 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 426 | 0.040 |
Why?
|
RNA Splicing | 1 | 2024 | 907 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 2 | 2022 | 4554 | 0.040 |
Why?
|
Prospective Studies | 1 | 2023 | 53288 | 0.040 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3462 | 0.040 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2023 | 871 | 0.040 |
Why?
|
Genotype | 2 | 2024 | 12951 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 973 | 0.040 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 246 | 0.030 |
Why?
|
Adolescent | 2 | 2021 | 85781 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2024 | 39050 | 0.030 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2015 | 92 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2024 | 2440 | 0.030 |
Why?
|
Animals | 4 | 2020 | 168757 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 367 | 0.030 |
Why?
|
DNA Repair | 1 | 2024 | 2046 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 222 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9438 | 0.030 |
Why?
|
Neoplasms | 2 | 2021 | 21683 | 0.030 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 294 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 2959 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2021 | 2513 | 0.030 |
Why?
|
Retreatment | 1 | 2015 | 610 | 0.030 |
Why?
|
DNA Damage | 1 | 2024 | 2432 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 755 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 380 | 0.030 |
Why?
|
Phenotype | 2 | 2024 | 16365 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2020 | 1179 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2085 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1878 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2429 | 0.020 |
Why?
|
Young Adult | 2 | 2021 | 56430 | 0.020 |
Why?
|
Transcription Factors | 2 | 2024 | 12208 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2022 | 3023 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3670 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5007 | 0.020 |
Why?
|
Thalidomide | 1 | 2015 | 890 | 0.020 |
Why?
|
Chromatin | 1 | 2022 | 2934 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2016 | 10481 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6538 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2022 | 3647 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2016 | 1581 | 0.020 |
Why?
|
Pneumonia | 1 | 2020 | 2133 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2021 | 3386 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2020 | 5097 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2504 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12026 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1799 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10180 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2488 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2942 | 0.020 |
Why?
|
Incidence | 1 | 2023 | 20947 | 0.020 |
Why?
|
Internet | 1 | 2016 | 3064 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2021 | 11483 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3703 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81183 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 5987 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 9959 | 0.010 |
Why?
|
Child | 1 | 2021 | 77709 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 72290 | 0.010 |
Why?
|